Michel R Langlois1,2,3, Allan D Sniderman4. 1. Department of Laboratory Medicine, AZ St-Jan Hospital, Ruddershove 10, B-8000, Bruges, Belgium. michel.langlois@azsintjan.be. 2. Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. michel.langlois@azsintjan.be. 3. Working Group on Guidelines, European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), Brussels, Belgium. michel.langlois@azsintjan.be. 4. Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Division of Cardiology, Royal Victoria Hospital-McGill University Health Centre, Montreal, Quebec, Canada.
Abstract
PURPOSE OF REVIEW: Guidelines propose using non-HDL cholesterol or apolipoprotein (apo) B as a secondary treatment target to reduce residual cardiovascular risk of LDL-targeted therapies. This review summarizes the strengths, weaknesses, opportunities, and threats (SWOT) of using apoB compared with non-HDL cholesterol. RECENT FINDINGS: Non-HDL cholesterol, calculated as total-HDL cholesterol, includes the assessment of remnant lipoprotein cholesterol, an additional risk factor independent of LDL cholesterol. ApoB is a direct measure of circulating numbers of atherogenic lipoproteins, and its measurement can be standardized across laboratories worldwide. Discordance analysis of non-HDL cholesterol versus apoB demonstrates that apoB is the more accurate marker of cardiovascular risk. Baseline and on-treatment apoB can identify elevated numbers of small cholesterol-depleted LDL particles that are not reflected by LDL and non-HDL cholesterol. ApoB is superior to non-HDL cholesterol as a secondary target in patients with mild-to-moderate hypertriglyceridemia (175-880 mg/dL), diabetes, obesity or metabolic syndrome, or very low LDL cholesterol < 70 mg/dL. When apoB is not available, non-HDL cholesterol should be used to supplement LDLC.
PURPOSE OF REVIEW: Guidelines propose using non-HDL cholesterol or apolipoprotein (apo) B as a secondary treatment target to reduce residual cardiovascular risk of LDL-targeted therapies. This review summarizes the strengths, weaknesses, opportunities, and threats (SWOT) of using apoB compared with non-HDL cholesterol. RECENT FINDINGS: Non-HDL cholesterol, calculated as total-HDL cholesterol, includes the assessment of remnant lipoprotein cholesterol, an additional risk factor independent of LDL cholesterol. ApoB is a direct measure of circulating numbers of atherogenic lipoproteins, and its measurement can be standardized across laboratories worldwide. Discordance analysis of non-HDL cholesterol versus apoB demonstrates that apoB is the more accurate marker of cardiovascular risk. Baseline and on-treatment apoB can identify elevated numbers of small cholesterol-depleted LDL particles that are not reflected by LDL and non-HDL cholesterol. ApoB is superior to non-HDL cholesterol as a secondary target in patients with mild-to-moderate hypertriglyceridemia (175-880 mg/dL), diabetes, obesity or metabolic syndrome, or very low LDL cholesterol < 70 mg/dL. When apoB is not available, non-HDL cholesterol should be used to supplement LDLC.
Authors: Emil Hagström; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Nicolas Danchin; Rafael Diaz; Shaun G Goodman; Robert A Harrington; J Wouter Jukema; Evangelos Liberopoulos; Nikolaus Marx; Jennifer McGinniss; Garen Manvelian; Robert Pordy; Michel Scemama; Harvey D White; Andreas M Zeiher; Gregory G Schwartz Journal: Circulation Date: 2022-06-30 Impact factor: 39.918
Authors: Harold E Bays; Pam R Taub; Elizabeth Epstein; Erin D Michos; Richard A Ferraro; Alison L Bailey; Heval M Kelli; Keith C Ferdinand; Melvin R Echols; Howard Weintraub; John Bostrom; Heather M Johnson; Kara K Hoppe; Michael D Shapiro; Charles A German; Salim S Virani; Aliza Hussain; Christie M Ballantyne; Ali M Agha; Peter P Toth Journal: Am J Prev Cardiol Date: 2021-01-23
Authors: Henry N Ginsberg; Chris J Packard; M John Chapman; Jan Borén; Carlos A Aguilar-Salinas; Maurizio Averna; Brian A Ference; Daniel Gaudet; Robert A Hegele; Sander Kersten; Gary F Lewis; Alice H Lichtenstein; Philippe Moulin; Børge G Nordestgaard; Alan T Remaley; Bart Staels; Erik S G Stroes; Marja-Riitta Taskinen; Lale S Tokgözoğlu; Anne Tybjaerg-Hansen; Jane K Stock; Alberico L Catapano Journal: Eur Heart J Date: 2021-12-14 Impact factor: 29.983